OncoGenex Raises Cash For Prostate Cancer Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
OncoGenex raises $50 million in cash to support the development of its earlier stage oncology assets.
You may also be interested in...
Financings Of The Fortnight Sees The Blooming Of New Life Sciences Funding Sources In The EU
Plus news on recent financing activity by Aastrom Biosciences, Tarsa Therapeutics, OncoGenex and Medivation.
OncoGenex/Teva Alter Late-Stage Custirsen Program
Teva and OncoGenex announced changes to the Phase III program of their prostate cancer drug custirsen on the heels of positive data from a competitor.
Prostate Cancer Market Snapshot: More Than Provenge
The launch of two drugs for metastatic prostate cancer this year – Dendreon Corp.'s Provenge (sipuleucel-T) and Sanofi-Aventis SA's Jevtana (cabazitaxel) – is shining a spotlight on an area of oncology that for many years was marked by a dearth of new treatment options.